AOD-9604 cycle length: what the human trial data actually supports

Last updated 2026-07-24

Is there an official or proven AOD-9604 cycle length?

No. That's the honest answer, and it's the one most sellers won't lead with. AOD-9604 went through actual human obesity trials in the mid-2000s, run by the Australian company Metabolic Pharmaceuticals. A 2004 review in Current Opinion in Investigational Drugs covered the compound's development as a metabolic fragment of human growth hormone, engineered to isolate the fat-metabolizing region of the GH molecule without the growth-promoting effects ^[1]. A follow-up 2006 review of obesity drugs in clinical development placed AOD-9604 in the pipeline alongside other anti-obesity candidates of that era ^[2]. The trials ran on the order of 12 to 24 weeks in published protocol descriptions, which is where most of the "cycle length" numbers floating around forums actually originate. But here's the part that gets dropped in translation: the weight-loss results from those trials did not separate convincingly from placebo. That's not a minor asterisk. It's the central finding. A compound with an unconvincing efficacy signal doesn't have a validated dose-and-duration protocol, because there's no clean endpoint to build one around. So when you see "12-week cycle" or "6-month cycle" claims for AOD-9604, understand what you're looking at: an extrapolation from trial duration, not a demonstrated optimal window. Nobody has published data showing that 8 weeks underperforms 16 weeks, or that a 4-week break resets anything. If you want dosing mechanics on top of this, our AOD-9604 dosage guide covers what's typically discussed, but the same caveat applies there too.

How long did the actual AOD-9604 obesity trials run?

The published trial record for AOD-9604 centers on the Metabolic Pharmaceuticals-sponsored obesity studies from the early-to-mid 2000s, most of which ran in the 12 to 24 week range based on how they're described in the investigational drug literature ^[1][2]. These were the trials meant to establish whether the fragment could drive meaningful fat loss in humans. The rationale itself is worth explaining honestly, because it's genuinely clever biochemistry even if the outcome disappointed. Human growth hormone has multiple functional domains. One region drives cell growth (the part responsible for GH's anabolic and diabetogenic effects), and a separate C-terminal fragment, roughly amino acids 176-191, appeared in animal and in vitro work to retain lipolytic activity (fat breakdown) without the growth-hormone-receptor binding that causes blood sugar problems and tissue growth. That fragment is AOD-9604. The idea was: keep the fat-burning switch, remove the parts that cause GH's downsides. It's a reasonable hypothesis. It just didn't hold up cleanly when tested in people over the trial durations used. The 2004 metabolic review is explicit that this was a fragment developed specifically for its metabolic (not growth) effects, tested as an anti-obesity candidate ^[1]. What it doesn't report is a clean, replicated, dose-dependent weight-loss effect beating placebo by a clinically meaningful margin over those weeks of dosing. That's the trial record. Weeks of dosing, a real mechanism on paper, and a result that didn't clearly beat sugar water.

Why didn't AOD-9604 separate from placebo in human trials?

Nobody has a fully satisfying mechanistic answer to this, and anyone who claims certainty is guessing. What's known is narrower: the human obesity trial data for AOD-9604, as characterized in the investigational drug pipeline literature, didn't produce a weight-loss signal that clearly outperformed placebo ^[1][2]. A few honest possibilities, none proven: the isolated fragment may lack sufficient potency at the doses and durations tested. The lipolytic activity seen in preclinical or in vitro models may not translate at meaningful magnitude in free-living humans eating normally. Or the trial designs (duration, dose selection, population) simply weren't sensitive enough to detect a real but small effect. All three are plausible. None of them justifies confidence that a longer cycle, a higher dose, or a different injection schedule would flip the result. This matters directly for cycle length. If a drug's effect scaled reliably with time on it, you could make an evidence-based case for a longer cycle. AOD-9604 doesn't have that kind of dose-response or duration-response data published. Stretching a cycle from 12 weeks to 24 weeks is not supported by anything in the record; it's just more weeks of an effect that wasn't clearly there in the first place.

What's a realistic AOD-9604 cycle length if someone chooses to use it?

If you're going to use it despite the weak trial record, the only grounding you have is the trial duration itself, roughly 12 to 24 weeks based on the obesity study descriptions in the literature ^[1][2]. That's not a recommendation, it's just the only timeframe with any human data attached to it at all. A practical, conservative approach some people follow: an 8 to 12 week block, then a real assessment (weight, waist measurement, how clothes fit, bloodwork if you're tracking anything), before deciding whether to continue. There's no evidence that cycling on and off changes anything meaningfully, because there's no strong evidence the compound is doing much in the first place. The stop-and-reassess approach isn't a peptide-science recommendation. It's just basic self-experimentation hygiene: don't keep paying for and injecting something for months without checking if it's working. Here's the table version of what's actually documented versus what's inferred:

For the injection and reconstitution mechanics if you're moving forward anyway, see how to reconstitute AOD-9604 and the AOD-9604 dosage calculator.

Does AOD-9604 need a break or off-cycle period like other peptides?

There's no published human data addressing this question directly for AOD-9604 specifically. The compound isn't a hormone replacement therapy with a feedback-loop suppression concern the way, say, exogenous testosterone or full-length GH can be, because the whole design intent was to strip out the growth-hormone-receptor-binding domain that drives those systemic effects ^[1]. That said, "no known suppression mechanism" is not the same as "safe to run indefinitely with data to back it." It just means the specific concern that drives cycling protocols for actual hormones doesn't obviously apply here. Nobody has run a 12-month continuous-use trial and compared it to an on/off protocol. If a decision has to be made without data, running defined blocks (8-12 weeks) with a stop point to reassess is simply more prudent than open-ended, indefinite use of something whose efficacy signal was already weak in short trials.

How does AOD-9604's evidence compare to GLP-1 drugs for cycle-length decisions?

This is the comparison that actually matters if you're deciding what to spend months of money and injections on. GLP-1 receptor agonists (semaglutide, tirzepatide) have gone through large, multi-year, placebo-controlled phase 3 trials with FDA approval and clear, replicated, dose-dependent weight-loss data measured in double-digit percentages of body weight over 68+ weeks. You can look those approvals up directly in the FDA's own drug database [FDA Drugs@FDA database, accessdata.fda.gov]. AOD-9604 has never received that kind of approval and never produced that kind of dose-response curve in its own obesity trials ^[1][2]. That's not a subtle difference. It's the difference between "here is a validated cycle length backed by a dose-response curve across a large trial population" and "here is a rough window of weeks that a smaller company used in its own studies, which then didn't clearly beat placebo." If your priority is weight loss with the strongest evidence behind the number on the scale, GLP-1 drugs currently have far more human trial weight behind them than AOD-9604 does. If you're specifically interested in AOD-9604 for reasons other than aggressive fat loss (some people are drawn to the fragment because it's marketed as free of GH's growth and blood-sugar side effects), that's a different conversation, but it's not a weight-loss guarantee either.

Is AOD-9604 detectable in drug testing, and does that affect cycle timing?

Yes, it's detectable, and this matters if you're an athlete subject to WADA testing and thinking about cycle timing around competition. A 2013 study in Drug Testing and Analysis specifically examined whether AOD-9604 interferes with the WADA hGH isoform immunoassay and found it does not influence that particular test ^[3]. That doesn't mean AOD-9604 is undetectable by every method, it means it doesn't cross-react with or mask the specific isoform test used to catch full-length GH doping. Separate detection science has moved toward peptide-specific methods: a 2014 review in Expert Review of Proteomics covers approaches for detecting peptidic drugs and analogs including small peptides like AOD-9604 in doping controls ^[4], and a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covers analytical methods for catching emerging, non-approved therapeutics in human doping samples ^[5]. A 2016 method in the Journal of Separation Science specifically describes screening for peptides under 2 kDa (AOD-9604 is roughly 1.8 kDa) via direct urine injection and mass spectrometry ^[6]. Practically: if you're tested, assume modern anti-doping labs have a pathway to find AOD-9604 specifically, even though it won't trip the older hGH isoform test ^[3]. Cycle timing built around "it won't show up" is not a safe assumption given where detection methodology has gone.

What does AOD-9604 research outside obesity trials say about duration of use?

Recent literature has looked at AOD-9604 in contexts other than fat loss, mostly orthopedic and musculoskeletal research, and duration data there is just as thin. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics generally, including applications, challenges, and future directions, and references AOD-9604 among the peptides discussed for musculoskeletal contexts ^[7]. A separate 2026 review in Sports Medicine covers the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again situating AOD-9604 within that broader unapproved-peptide category ^[8]. Neither of these establishes a validated cycle length for AOD-9604 in any indication. They confirm that researchers are still actively characterizing where this peptide might or might not have a real effect, years after the original obesity trials ended without a clean win. If anything, the fact that AOD-9604 keeps showing up in review articles as an "unapproved" peptide worth further study, rather than as an approved therapy with dosing guidelines, tells you where the regulatory and evidence status actually sits.

Where does AOD-9604 stand legally, and does that affect how it's cycled?

AOD-9604 is not an FDA-approved drug for any indication. You can confirm this directly by searching the FDA's own Drugs@FDA database [FDA Drugs@FDA database, accessdata.fda.gov], which lists approved drug products and does not include AOD-9604 as an approved therapy. This matters for cycle-length planning because there's no FDA-approved label with dosing and duration instructions to lean on, the way there is for an approved drug. It also matters for how it's legally sourced. Compounding pharmacies operating under section 503A of the Food, Drug and Cosmetic Act, per 21 U.S.C. 353a ^[9], may only compound using bulk drug substances that meet specific criteria, and the FDA maintains lists of substances that can and cannot be used under 503A (21 CFR 216.23 ^[10]) and 503B (21 CFR 216.24 ^[11]) respectively. The FDA's own bulk drug substance page for 503A compounding explains the nomination and evaluation process ^[12], and the agency's current bulk substance nomination list is public ^[13]. What this means practically: whether AOD-9604 can legally be compounded and dispensed depends on its status on these FDA bulk substance lists, which changes over time and is worth checking directly rather than trusting a seller's claim. This is also the reason legitimate, provider-reviewed sourcing matters more than cycle-length optimization. A peptide obtained without any pharmacy or prescriber review carries risks (purity, dosing accuracy, contamination) that no cycle-length strategy fixes. If you're evaluating where to source it, see AOD-9604 for sale for what provider-reviewed sourcing actually looks like, and go through AOD-9604 Co's provider-reviewed route with its fulfilling pharmacy partner rather than an unverified supplier.

What side effects should influence how long someone runs a cycle?

Side-effect data specific to long cycles of AOD-9604 in humans is limited, mostly because the trials that exist ran for defined, relatively short windows (12-24 weeks) rather than open-ended use ^[1][2]. The theoretical appeal of the fragment was always that, by design, it shouldn't carry full-length GH's known issues, since the growth-hormone-receptor-binding region was deliberately removed ^[1]. That's a design intent, not a guarantee proven across long-term human use. If you're planning any cycle length, injection site reactions, general peptide-related side effects, and individual response should shape the decision more than an arbitrary week count. For a fuller breakdown of what's reported and what's theoretical, see AOD-9604 side effects before deciding how long to run anything.

So what's the actual bottom line on cycle length?

There isn't a scientifically validated AOD-9604 cycle length, because there isn't a scientifically validated AOD-9604 weight-loss effect to build one around. The human obesity trials ran roughly 12 to 24 weeks and didn't produce a weight-loss result that clearly separated from placebo ^[1][2]. Any specific week-count protocol you see quoted is derived from trial duration, not from proven optimal dosing. The most defensible approach, if you're set on trying it, is short blocks (8-12 weeks), honest tracking of actual outcomes, and a real decision point about whether to continue, rather than committing to months of use on the assumption that a longer cycle fixes what a 12-week trial couldn't show. And if fat loss with strong trial backing is the actual goal, it's worth being honest that GLP-1 drugs currently have a far deeper and more convincing human evidence base behind their dosing schedules than AOD-9604 does. For the mechanism and full trial history, read what AOD-9604 peptide actually is and what the evidence shows.

Frequently asked questions

What is the standard AOD-9604 cycle length?

There's no standard, validated cycle length. The human obesity trials that tested AOD-9604 ran roughly 12 to 24 weeks, but the weight-loss results in those trials didn't clearly beat placebo ^[1][2], so there's no proven duration to recommend. Any specific week count you see quoted online is an estimate based on trial length, not a demonstrated optimal protocol.

Can you run AOD-9604 for 6 months straight?

Nobody has published human trial data testing continuous 6-month use, so there's no evidence it's more effective or less safe than shorter use. Given the weak efficacy signal in the shorter 12-24 week trials ^[1][2], running it for 6 months without reassessing results partway through isn't well supported by anything in the trial record.

Does AOD-9604 need a break between cycles?

There's no published data on cycling on and off AOD-9604 specifically. Because the fragment was designed to exclude the growth-hormone-receptor-binding domain, the suppression concerns that drive cycling protocols for actual hormones don't clearly apply, but that's inference, not trial evidence. A defined stop point for reassessment is prudent regardless.

Why did AOD-9604 fail its obesity trials?

The exact reason isn't established. What's documented is that AOD-9604's human obesity trials didn't produce weight loss that separated convincingly from placebo ^[1][2]. Possible explanations include insufficient potency at tested doses, weak translation from preclinical lipolytic activity to real-world fat loss, or trial designs not sensitive enough to detect a small true effect. None is proven.

Is AOD-9604 detectable in a drug test during a cycle?

Yes. A 2013 study confirmed AOD-9604 doesn't interfere with the WADA hGH isoform immunoassay ^[3], but separate peptide-specific detection methods, including mass spectrometry screening for peptides under 2 kDa, have been developed and can identify it directly ^[4][5][6]. Assume it's detectable by modern anti-doping labs regardless of cycle timing.

How does AOD-9604's cycle evidence compare to semaglutide or tirzepatide?

GLP-1 drugs like semaglutide and tirzepatide have FDA-approved labeling built on large, multi-year phase 3 trials with clear dose-response weight-loss data, confirmed through the FDA's own Drugs@FDA database. AOD-9604 has no FDA approval and its own obesity trials didn't clearly beat placebo ^[1][2], so there's far less evidence behind any AOD-9604 dosing schedule by comparison.

Should I stop AOD-9604 if I don't see results after 12 weeks?

That's a reasonable point to reassess, since 12 weeks sits within the range used in the actual human trials ^[1][2]. Given the trial record showed no convincing separation from placebo at these durations, continuing for additional months without any measurable change isn't well supported by the existing evidence.

Is AOD-9604 legal to buy and use?

AOD-9604 isn't FDA-approved for any use, per the FDA's Drugs@FDA database. Whether it can be legally compounded depends on its status on the FDA's bulk drug substance lists for 503A ^[10] and 503B ^[11] compounding under 21 U.S.C. 353a ^[9], which changes over time, so check current status through provider-reviewed sourcing rather than a seller's claim.

Does a longer AOD-9604 cycle produce better fat loss results?

There's no published dose-response or duration-response data showing this. The trials that tested AOD-9604 for obesity ran 12 to 24 weeks and didn't show a weight-loss effect that clearly beat placebo at those durations ^[1][2], so there's no evidence base suggesting longer cycles improve outcomes.

What's the difference between AOD-9604 and full-length HGH for cycling purposes?

AOD-9604 is a fragment (amino acids 176-191) designed to isolate GH's fat-metabolizing activity while removing the growth-hormone-receptor-binding region responsible for GH's anabolic and blood-sugar effects ^[1]. That design intent is the whole rationale, but it hasn't translated into a proven fat-loss advantage in human obesity trials, unlike full-length GH which has established, if different, approved uses.

Can AOD-9604 be combined with GLP-1 drugs during a cycle?

No published human trial data addresses combining AOD-9604 with GLP-1 receptor agonists. Given AOD-9604's own obesity trials didn't show a clear weight-loss effect versus placebo ^[1][2], there's no evidence basis for expecting added benefit from combining it with a separately, more strongly validated therapy.

How is AOD-9604 typically sourced for a cycle?

It's not FDA-approved, so it isn't dispensed the way an approved prescription drug is. Where it's compounded, that has to happen under 503A or 503B rules and current FDA bulk substance list status ^[9][10][11]. Provider-reviewed sourcing through a fulfilling pharmacy partner is the safer route compared to unverified suppliers with no quality oversight.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604 is a GH fragment developed specifically for its metabolic (fat-related) effects, and this review covers its metabolic profile as an investigational obesity drug.
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 was listed among obesity drugs in clinical development in the mid-2000s pipeline review.
3. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence or interfere with the WADA hGH isoform immunoassay used in anti-doping testing.
4. PubMed, Expert Review of Proteomics (2014): Reviews current and future analytical methods for detecting peptidic drugs, candidates, and analogs like AOD-9604 in sports doping controls.
5. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Covers analytical approaches for detecting emerging therapeutics and non-approved drugs, including small peptides, in human doping controls.
6. PubMed, Journal of Separation Science (2016): Describes a method for screening peptides under 2 kDa, the size class that includes AOD-9604, via direct urine injection and mass spectrometry.
7. PubMed, JAAOS Global Research & Reviews (2026): Reviews therapeutic peptides in orthopaedics, including applications, challenges, and future directions, referencing AOD-9604 among peptides studied in musculoskeletal contexts.
8. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, situating AOD-9604 as an unapproved peptide studied in that space.
9. Cornell Law School, 21 U.S.C. 353a: Establishes the federal statutory framework (section 503A) governing pharmacy compounding of drugs.
10. eCFR, 21 CFR 216.23: Lists the bulk drug substances that may be used in compounding under section 503A.
11. eCFR, 21 CFR 216.24: Lists the bulk drug substances that may be used in compounding under section 503B.
12. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA process for evaluating and nominating bulk drug substances for use in 503A compounding.
13. FDA, Bulk Drug Substances Nominated for Use in Compounding: Current FDA list of bulk drug substances nominated for compounding use, relevant to whether a substance like AOD-9604 can be legally compounded.